Journal of Wildlife Diseases · 2011 · 24 citations · 20 references
PharmacyPharmacokineticsPharmacologyClinical PharmacologyPharmaceutical ToxicologyPopulation PharmacokineticsAnthelmintic PharmacologyDrug DispositionAnalytical Liquid ChromatographyDrug Elimination Half-lifeOff-label Drug Use RegulationPeak Plasma Concentration ChangesPharmacokinetic ParametersPharmacokinetics Of Subcutaneous AdministrationTandem Mass SpectrometryTandem Mass Spectrometry Analysis
Sarcoptic mange, caused by Sarcoptes scabiei var. wombati, could be a significant threat to populations of southern hairy-nosed wombats (Lasiorhinus latifrons; SHNW) in Australia. Treatment is currently based on the off-label use of various parasiticidal drugs, with limited clinical efficacy trials. Our primary aim was to determine the pharmacokinetic parameters of a macrocyclic lactone, moxidectin, to assist in the development of effective treatment protocols. Pharmacokinetic parameters were determined in four female SHNW following a single subcutaneous injection of 0.2 mg/kg moxidectin. Blood samples were collected for 38 days following injection (August-September 2008), for analysis using liquid chromatography and tandem mass spectrometry. The mean peak plasma concentration occurred at 13.6 hr, with a mean peak plasma level of 98.6 ng/ml. The mean elimination half-life was 5.03 days, resulting in a mean area under the curve of 377 ng.day/ml. The peak plasma moxidectin concentration was higher than that seen in livestock species but the plasma elimination half-life was shorter. This study suggests that a single injection of 0.2 mg/kg moxidectin may not be sufficient to clear a mange infection in this species.
20
Bioanalytical Method Validation—A Revisit with a Decade of Progress
Vinod P. Shah, Kamal K. Midha, John W. A. Findlay et al. · Pharmaceutical Research · 2000 · 1.6K citations
The development of protective immunity in canine scabies
Larry G. Arlian, Marjorie S. Morgan, Christine M. Rapp et al. · Veterinary Parasitology · 1996 · 103 citations